Alpha Cognition Corp - רווח נקי למניה (EPS TTM) ACOG

The market for cognitive decline treatments possesses colossal potential, which can be tracked via the stock price trend on GURU.Markets, where the EPS stands at 30.90. The prosperity of Alpha Cognition (ACOG) relies on patents and the proven efficacy of dementia therapy. However, potential trial failures and pressure from corporate behemoths during regulatory reviews pose a serious threat.

Year-over-year (TTM) EPS growth measures the percentage change in net income per share over the last twelve months relative to the same period last year. This rolling-year EPS percentage change trend allows for an assessment of profit scaling rates. The calculation is based on a comparison of rolling quarterly data to neutralize seasonality. For Alpha Cognition (ACOG), this indicator will become key when launching the drug into the cognitive disorder treatment market.